1
FDA Grants Survodutide Breakthrough Therapy Designation for MASH
The FDA granted breakthrough therapy designation to survodutide, a dual glucagon/GLP-1 receptor agonist by Boehringer Ingelheim, for treating adults with MASH.
FDA Approves Oral Semaglutide and Higher Ozempic Dose, Survodutide Breakthrough Designation, Cyclic Peptide Oral Insulin Breakthrough
FDA approves oral semaglutide pill and higher Ozempic dose, grants survodutide breakthrough designation for MASH, and oral insulin via cyclic peptides advances.
10 stories · Covering regulatory, research, clinical-trials, industry
Editor's Note
Today's peptide landscape is dominated by a wave of FDA actions, next-generation drug delivery breakthroughs, and the booming unregulated peptide market. The FDA approved oral semaglutide as the first GLP-1 pill for weight loss, a higher 2 mg dose of Ozempic, IMCIVREE for hypothalamic obesity, and granted survodutide breakthrough therapy designation for MASH — four regulatory milestones in 48 hours. Kumamoto University researchers published a landmark study showing a cyclic peptide platform can deliver insulin orally with 33–41% bioavailability. On the clinical front, Retatrutide continues to impress with TRIUMPH Phase 3 data showing up to 24% weight loss.
2
Cyclic Peptide Platform Enables Oral Insulin With 33-41% Bioavailability
Kumamoto University researchers developed a cyclic peptide (DNP peptide) that enables oral insulin delivery through the intestinal wall — a dramatic improvement that could end the century-long dependence on injections.
3
IMCIVREE Wins FDA Approval for Acquired Hypothalamic Obesity
FDA approved setmelanotide (IMCIVREE), an MC4R agonist peptide, for reducing body weight in adults and children aged 4+. Phase 3 TRANSCEND trial showed 18.4% placebo-adjusted BMI reduction at 52 weeks.
4
FDA Approves Higher 2 mg Dose of Ozempic for Type 2 Diabetes
The FDA approved a new 2 mg dose of Ozempic (semaglutide) injection, providing an additional option for patients needing more intensive glycemic management.
5
TRIUMPH Phase 3 Program Shows Retatrutide Achieves Up to 24% Weight Loss
Analysis of the TRIUMPH program (TRIUMPH-1 through TRIUMPH-4) published in Diabetes, Obesity, and Metabolism shows unprecedented average weight reduction of up to 24% across 5,800+ adults.
6
Semaglutide Linked to 42% Drop in Psychiatric Hospital Visits
Large-scale study from University of Eastern Finland and Karolinska Institutet found GLP-1 medications associated with 42% drop in psychiatric hospital visits, 44% lower depression risk, and 47% reduced substance use disorders.
7
Cagrilintide Shows Promising Phase 3 Results as Standalone Obesity Therapy
Phase 3 trial results show cagrilintide, an amylin analogue peptide, achieved significant weight loss as a standalone therapy — a new peptide-based approach distinct from GLP-1 agonists.
8
Zealand Pharma Opens U.S. Research Hub in Cambridge, MA
Zealand Pharma announced a new Cambridge research hub combining 25+ years of peptide expertise with AI-driven drug discovery, expanding its obesity and metabolic health pipeline.
9
WBUR/NPR: People Buying Unregulated Injectable Peptides From Chinese Factories
Investigative journalist documents how consumers buy injectable peptides from Chinese factories via social media and Reddit. The global peptide market has swelled to $50 billion annually.
10
BPC-157 Evidence Review: 544 Papers, Only 3 Human Studies, Zero RCTs
In-depth review examined 544 BPC-157 papers and found only 3 human studies and zero randomized controlled trials. Author recommends most people avoid it until stronger evidence emerges.